TrialAnnals of the rheumatic diseases2021

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.